Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature
Leukemia Research, 06/19/09
Guastafierro S et al. - The authors report the case of a 20-years-old male patient in chronic phase CML who maintained undetectable BCR/ABL mRNA levels, despite IM discontinuation over a period of 15 months after achieving CMR.
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Hodgkin's lymphoma in remission after first-line therapy: Which patients need FDG-PET/CT for follow-up?
Annals of Oncology, 11/17/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Primary extranodal marginal zone lymphoma of the uvea associated with massive diffuse epibulbar extension and focal infiltration of the optic nerve and meninges, clinically presented as uveitis masquerade syndrome: a case report
Medical Oncology, 10/16/09
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma
American Journal of Hematology, 11/10/09
An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
Anticancer Research, 11/13/09
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Leukemia, 11/17/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


